{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:36:03Z","timestamp":1793637363671,"version":"4.5.1"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Histol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10735-025-10507-2","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T03:34:19Z","timestamp":1753241659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD)"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-7567","authenticated-orcid":false,"given":"Neha","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"10507_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/978-981-97-9519-2_3","volume":"15","author":"L Abenavoli","year":"2024","unstructured":"Abenavoli L, Scarlata GGM (2024) Decoding MASLD\u2019s Pathophysiology. Metab Dysfunct Assoc Steatotic Liver Dis Preval Res Insights Future Dir 15:24. https:\/\/doi.org\/10.1007\/978-981-97-9519-2_3","journal-title":"Metab Dysfunct Assoc Steatotic Liver Dis Preval Res Insights Future Dir"},{"key":"10507_CR2","doi-asserted-by":"publisher","first-page":"52982","DOI":"10.3791\/52982","volume":"102","author":"TE Akie","year":"2015","unstructured":"Akie TE, Cooper MP (2015) Determination of Fatty Acid Oxidation and Lipogenesis in Mouse Primary Hepatocytes. J vis Exp 102:52982. https:\/\/doi.org\/10.3791\/52982","journal-title":"J vis Exp"},{"key":"10507_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.REDOX.2018.04.002","volume":"17","author":"F Alhasson","year":"2018","unstructured":"Alhasson F, Seth RK, Sarkar S, Kimono DA, Albadrani MS, Dattaroy D, Chandrashekaran V, Scott GI, Raychoudhury S, Nagarkatti M, Nagarkatti P, Diehl AM, Chatterjee S (2018) High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease. Redox Biol 17:1\u201315. https:\/\/doi.org\/10.1016\/J.REDOX.2018.04.002","journal-title":"Redox Biol"},{"key":"10507_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM-JW.NA57292","author":"S Allan","year":"2024","unstructured":"Allan S, Brett M (2024) Resmetirom, the first drug approved by the U.S. FDA for treating patients with nonalcoholic steatohepatitis. NEJM J Watch. https:\/\/doi.org\/10.1056\/NEJM-JW.NA57292","journal-title":"NEJM J Watch."},{"issue":"3","key":"10507_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ecl.2023.01.003","volume":"52","author":"SD Anwar","year":"2023","unstructured":"Anwar SD, Foster C, Ashraf A (2023) Lipid disorders and metabolic-associated fatty liver disease. Endocrinol Metab Clin North Am 52(3):445\u2013457. https:\/\/doi.org\/10.1016\/j.ecl.2023.01.003","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9","key":"10507_CR6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/J.BBADIS.2015.05.015","volume":"1852","author":"G Arguello","year":"2015","unstructured":"Arguello G, Balboa E, Arrese M, Zanlungo S (2015) Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica Et Biophysica Acta (BBA)- Mol Basic Dis 1852(9):1765\u20131778. https:\/\/doi.org\/10.1016\/J.BBADIS.2015.05.015","journal-title":"Biochimica Et Biophysica Acta (BBA)- Mol Basic Dis"},{"issue":"2","key":"10507_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ANTIOX10020174","volume":"10","author":"JC Arroyave-Ospina","year":"2021","unstructured":"Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H (2021) Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy. Antioxidants 10(2):174. https:\/\/doi.org\/10.3390\/ANTIOX10020174","journal-title":"Antioxidants"},{"issue":"9","key":"10507_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.46234","volume":"15","author":"JD Bade","year":"2023","unstructured":"Bade JD, Veeramalla V, Naidu MBR, Lalitha DL, Ponnada SC, Kandi V (2023) Serum activities of paraoxonase 1 (PON1) in predicting liver damage among patients diagnosed with hepatocellular carcinoma: a case-control study. Cureus 15(9):e46234. https:\/\/doi.org\/10.7759\/CUREUS.46234","journal-title":"Cureus"},{"issue":"5","key":"10507_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/S00109-019-01765-1","volume":"97","author":"L Bai","year":"2019","unstructured":"Bai L, Li H (2019) Innate immune regulatory networks in hepatic lipid metabolism. J Mol Med 97(5):593\u2013604. https:\/\/doi.org\/10.1007\/S00109-019-01765-1","journal-title":"J Mol Med"},{"key":"10507_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/MEDICINA56020058","author":"M Banaszczak","year":"2020","unstructured":"Banaszczak M, Maciejewska D, Drozd A, Ryterska K, Milc DJ, Raszeja-Wyszomirska J, Wunsch E, Gonz\u00e1lez-Muniesa P, Stachowska E (2020) 5-lipooxygenase derivatives as serum biomarkers of a successful dietary intervention in patients with nonalcoholic fatty liver disease. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/MEDICINA56020058","journal-title":"Medicina (Kaunas)"},{"issue":"8","key":"10507_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/ANTIOX7080102","volume":"7","author":"G Barrera","year":"2018","unstructured":"Barrera G, Pizzimenti S, Daga M, Dianzani C, Arcaro A, Cetrangolo GP, Giordano G, Cucci MA, Graf M, Gentile F (2018) Lipid peroxidation-derived aldehydes, 4-hydroxynonenal and malondialdehyde in aging-related disorders. Antioxidants 7(8):102. https:\/\/doi.org\/10.3390\/ANTIOX7080102","journal-title":"Antioxidants"},{"key":"10507_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2018.01786","volume":"9","author":"N Berndt","year":"2018","unstructured":"Berndt N, Holzh\u00fctter HG (2018) Dynamic metabolic zonation of the hepatic glucose metabolism is accomplished by sinusoidal plasma gradients of nutrients and hormones. Front Physiol 9:419724. https:\/\/doi.org\/10.3389\/FPHYS.2018.01786","journal-title":"Front Physiol"},{"key":"10507_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/J.REDOX.2021.101882","volume":"41","author":"M Bortolotti","year":"2021","unstructured":"Bortolotti M, Polito L, Battelli MG, Bolognesi A (2021) Xanthine oxidoreductase: one enzyme for multiple physiological tasks. Redox Biol 41:101882. https:\/\/doi.org\/10.1016\/J.REDOX.2021.101882","journal-title":"Redox Biol"},{"issue":"8","key":"10507_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/J.METABOL.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8):1038\u20131048. https:\/\/doi.org\/10.1016\/J.METABOL.2015.12.012","journal-title":"Metabolism"},{"issue":"10","key":"10507_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/J.TEM.2018.08.003","volume":"29","author":"J Cai","year":"2018","unstructured":"Cai J, Zhang XJ, Li H (2018) Role of innate immune signaling in non-alcoholic fatty liver disease. Trends Endocrinol Metab 29(10):712\u2013722. https:\/\/doi.org\/10.1016\/J.TEM.2018.08.003","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10507_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/JOMES23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR (2023) Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr 32(3):197\u2013213. https:\/\/doi.org\/10.7570\/JOMES23052","journal-title":"J Obes Metab Syndr"},{"issue":"5","key":"10507_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cld.1061","volume":"17","author":"S Cheemerla","year":"2021","unstructured":"Cheemerla S, Balakrishnan M (2021) Global epidemiology of chronic liver disease. Clin Liver Dis 17(5):365\u2013370","journal-title":"Clin Liver Dis"},{"key":"10507_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2020.00433","volume":"11","author":"S Chen","year":"2020","unstructured":"Chen S, Chen H, Du Q, Shen J (2020) Targeting myeloperoxidase (MPO) mediated oxidative stress and inflammation for reducing brain ischemia injury: potential application of natural compounds. Front Physiol 11:528444. https:\/\/doi.org\/10.3389\/FPHYS.2020.00433","journal-title":"Front Physiol"},{"issue":"2","key":"10507_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/S12072-022-10443-3","volume":"17","author":"L Chen","year":"2023","unstructured":"Chen L, Fan Z, Sun X, Qiu W, Mu W, Chai K, Cao Y, Wang G, Lv G (2023) Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study. Hepatol Int 17(2):326\u2013338. https:\/\/doi.org\/10.1007\/S12072-022-10443-3","journal-title":"Hepatol Int"},{"issue":"1","key":"10507_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/J.LIVRES.2017.11.005","volume":"2","author":"H Chu","year":"2018","unstructured":"Chu H, Williams B, Schnabl B (2018) Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Res 2(1):43\u201351. https:\/\/doi.org\/10.1016\/J.LIVRES.2017.11.005","journal-title":"Liver Res"},{"key":"10507_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/J.NUMECD.2025.103926","author":"S Corrao","year":"2025","unstructured":"Corrao S, Scibetta S, Scardina S, Gran\u00e0 W, Bongiorno B, Calvo L, Volpato S (2025) Prevalence and association of metabolism-associated steatotic liver disease across age groups and gender. Nutr Metab Cardiovasc Dis. https:\/\/doi.org\/10.1016\/J.NUMECD.2025.103926","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10507_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/J.EPRAC.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z (2022) American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 28(5):528\u2013562. https:\/\/doi.org\/10.1016\/J.EPRAC.2022.03.010","journal-title":"Endocr Pract"},{"issue":"1","key":"10507_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/S10557-016-6706-X","volume":"31","author":"Y Dai","year":"2017","unstructured":"Dai Y, Cao Y, Zhang Z, Vallurupalli S, Mehta JL (2017) Xanthine oxidase induces foam cell formation through LOX-1 and NLRP3 activation. Cardiovasc Drugs Ther 31(1):19\u201327. https:\/\/doi.org\/10.1007\/S10557-016-6706-X","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10507_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22010436","volume":"22","author":"M Dallio","year":"2021","unstructured":"Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, Serviddio G, Federico A (2021) Immunity as cornerstone of non-alcoholic fatty liver disease: the contribution of oxidative stress in the disease progression. Int J Mol Sci 22(1):436. https:\/\/doi.org\/10.3390\/IJMS22010436","journal-title":"Int J Mol Sci"},{"key":"10507_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/J.PHARMTHERA.2019.05.011","volume":"201","author":"D Dalvie","year":"2019","unstructured":"Dalvie D, Di L (2019) Aldehyde oxidase and its role as a drug metabolizing enzyme. Pharmacol Ther 201:137\u2013180. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2019.05.011","journal-title":"Pharmacol Ther"},{"key":"10507_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/J.CBI.2019.108929","volume":"316","author":"EO Dangana","year":"2020","unstructured":"Dangana EO, Omolekulo TE, Areola ED, Olaniyi KS, Soladoye AO, Olatunji LA (2020) Sodium acetate protects against nicotine-induced excess hepatic lipid in male rats by suppressing xanthine oxidase activity. Chem Biol Interact 316:108929. https:\/\/doi.org\/10.1016\/J.CBI.2019.108929","journal-title":"Chem Biol Interact"},{"key":"10507_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2021.595371","volume":"8","author":"AP Delli Bovi","year":"2021","unstructured":"Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P (2021) Oxidative stress in non-alcoholic fatty liver disease. An updated mini review. Front Med 8:595371. https:\/\/doi.org\/10.3389\/FMED.2021.595371","journal-title":"Front Med"},{"key":"10507_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/J.COPH.2017.04.003","volume":"33","author":"S Deshwal","year":"2017","unstructured":"Deshwal S, Di Sante M, Di Lisa F, Kaludercic N (2017) Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease. Curr Opin Pharmacol 33:64\u201369. https:\/\/doi.org\/10.1016\/J.COPH.2017.04.003","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"10507_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ANTIOX9121283","volume":"9","author":"PV Dludla","year":"2020","unstructured":"Dludla PV, Nkambule BB, Mazibuko-Mbeje SE, Nyambuya TM, Marcheggiani F, Cirilli I, Ziqubu K, Shabalala SC, Johnson R, Louw J, Damiani E, Tiano L (2020) N-acetyl cysteine targets hepatic lipid accumulation to curb oxidative stress and inflammation in NAFLD: a comprehensive analysis of the literature. Antioxidants 9(12):1283. https:\/\/doi.org\/10.3390\/ANTIOX9121283","journal-title":"Antioxidants"},{"issue":"1","key":"10507_CR30","doi-asserted-by":"publisher","first-page":"9233650","DOI":"10.1155\/2022\/9233650","volume":"2022","author":"D Ezhilarasan","year":"2022","unstructured":"Ezhilarasan D, Lakshmi T (2022) A molecular insight into the role of antioxidants in nonalcoholic fatty liver diseases. Oxid Med Cell Longev 2022(1):9233650. https:\/\/doi.org\/10.1155\/2022\/9233650","journal-title":"Oxid Med Cell Longev"},{"key":"10507_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2390164","author":"R Feng","year":"2024","unstructured":"Feng R, Yang W, Feng W, Huang X, Cen M, Peng G, Wu W, Wang Z, Jing Y, Long T, Liu Y, Li Z, Chang G, Huang K (2024) Time-restricted feeding ameliorates non-alcoholic fatty liver disease through modulating hepatic nicotinamide metabolism via gut microbiota remodeling. Gut Microbes. https:\/\/doi.org\/10.1080\/19490976.2024.2390164","journal-title":"Gut Microbes"},{"issue":"3","key":"10507_CR32","doi-asserted-by":"publisher","first-page":"101271","DOI":"10.1016\/J.JHEPR.2024.101271","volume":"7","author":"G Feng","year":"2025","unstructured":"Feng G et al (2025) Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep 7(3):101271. https:\/\/doi.org\/10.1016\/J.JHEPR.2024.101271","journal-title":"JHEP Rep"},{"issue":"3","key":"10507_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3390\/ANTIOX12030711","volume":"12","author":"MD Ferrer","year":"2023","unstructured":"Ferrer MD, Reyn\u00e9s C, Monserrat-Mesquida M, Quetglas-Llabr\u00e9s M, Bouzas C, Garc\u00eda S, Mateos D, Casares M, G\u00f3mez C, Ugarriza L, Tur JA, Sureda A, Pons A (2023) Polyunsaturated and saturated oxylipin plasma levels allow monitoring the non-alcoholic fatty liver disease progression to severe stages. Antioxidants 12(3):711. https:\/\/doi.org\/10.3390\/ANTIOX12030711","journal-title":"Antioxidants"},{"issue":"24","key":"10507_CR34","doi-asserted-by":"publisher","first-page":"13219","DOI":"10.3390\/IJMS222413219","volume":"22","author":"B Filipovic","year":"2021","unstructured":"Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Kiswani JA, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A (2021) The new therapeutic approaches in the treatment of non-alcoholic fatty liver disease. Int J Mol Sci 22(24):13219. https:\/\/doi.org\/10.3390\/IJMS222413219","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10507_CR35","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/JCB.30247","volume":"123","author":"CM Flessa","year":"2022","unstructured":"Flessa CM, Kyrou I, Nasiri-Ansari N, Kaltsas G, Kassi E, Randeva HS (2022) Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD\/MAFLD). J Cell Biochem 123(10):1585\u20131606. https:\/\/doi.org\/10.1002\/JCB.30247","journal-title":"J Cell Biochem"},{"issue":"17","key":"10507_CR36","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMOA2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-G\u00f3mez M, Huot-Marchand P, Baudin M, Richard M-P, Abitbol J-L, Broqua P, Junien J-L, Abdelmalek MF (2021) A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med 385(17):1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMOA2036205","journal-title":"N Engl J Med"},{"issue":"10","key":"10507_CR37","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1124\/dmd.113.053082","volume":"41","author":"C Fu","year":"2013","unstructured":"Fu C, Di L, Han X, Soderstrom C, Snyder M, Troutman MD, Obach RS, Zhang H (2013) Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative characterization of AOX1 expression level and activity relationships. Drug Metab Dispos 41(10):1797\u20131804. https:\/\/doi.org\/10.1124\/dmd.113.053082","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10507_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4331\/WJBC.V9.I1.1","volume":"9","author":"J Fujii","year":"2018","unstructured":"Fujii J, Homma T, Kobayashi S, Seo HG (2018) Mutual interaction between oxidative stress and endoplasmic reticulum stress in the pathogenesis of diseases specifically focusing on non-alcoholic fatty liver disease. World J Biol Chem 9(1):1\u201315. https:\/\/doi.org\/10.4331\/WJBC.V9.I1.1","journal-title":"World J Biol Chem"},{"issue":"5","key":"10507_CR39","doi-asserted-by":"publisher","first-page":"E827","DOI":"10.1152\/AJPENDO.00378.2020","volume":"319","author":"M Furuhashi","year":"2020","unstructured":"Furuhashi M (2020) New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab 319(5):E827\u2013E834. https:\/\/doi.org\/10.1152\/AJPENDO.00378.2020","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"10507_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/BIOMEDICINES9060687","volume":"9","author":"D Gabbia","year":"2021","unstructured":"Gabbia D, Cannella L, De Martin S, Shiri-Sverdlov R, Squadrito G (2021) The role of oxidative stress in NAFLD\u2013NASH\u2013HCC transition\u2014focus on NADPH oxidases. Biomedicines 9(6):687. https:\/\/doi.org\/10.3390\/BIOMEDICINES9060687","journal-title":"Biomedicines"},{"issue":"2","key":"10507_CR41","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/J.ATHEROSCLEROSIS.2014.05.948","volume":"235","author":"SH Ganji","year":"2014","unstructured":"Ganji SH, Kamanna VS, Kashyap ML (2014) Niacin decreases leukocyte myeloperoxidase: mechanistic role of redox agents and Src\/p38MAP kinase. Atherosclerosis 235(2):554\u2013561. https:\/\/doi.org\/10.1016\/J.ATHEROSCLEROSIS.2014.05.948","journal-title":"Atherosclerosis"},{"issue":"2","key":"10507_CR42","doi-asserted-by":"publisher","first-page":"S771","DOI":"10.1007\/S12072-013-9468-6\/METRICS","volume":"7","author":"M Ganz","year":"2013","unstructured":"Ganz M, Szabo G (2013) Immune and inflammatory pathways in NASH. Hep Intl 7(2):S771\u2013S781. https:\/\/doi.org\/10.1007\/S12072-013-9468-6\/METRICS","journal-title":"Hep Intl"},{"issue":"4","key":"10507_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1517\/17425255.2012.663352","volume":"8","author":"E Garattini","year":"2012","unstructured":"Garattini E, Terao M (2012) The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8(4):487\u2013503. https:\/\/doi.org\/10.1517\/17425255.2012.663352","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10507_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1042\/BJ20030121","volume":"372","author":"E Garattini","year":"2003","unstructured":"Garattini E, Mendel R, Rom\u00e3o MJ, Wright R, Terao M (2003) Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 372(1):15\u201332. https:\/\/doi.org\/10.1042\/BJ20030121","journal-title":"Biochem J"},{"issue":"1","key":"10507_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep23664","volume":"6","author":"I Garc\u00eda-Ruiz","year":"2016","unstructured":"Garc\u00eda-Ruiz I, Sol\u00eds-Mu\u00f1oz P, Fern\u00e1ndez-Moreira D, Grau M, Mu\u00f1oz-Yag\u00fce T, Sol\u00eds-Herruzo JA (2016) NADPH oxidase is implicated in the pathogenesis of oxidative phosphorylation dysfunction in mice fed a high-fat diet. Sci Rep 6(1):1\u201313. https:\/\/doi.org\/10.1038\/srep23664","journal-title":"Sci Rep"},{"issue":"1","key":"10507_CR46","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-16-0513","volume":"234","author":"CE Geisler","year":"2017","unstructured":"Geisler CE, Renquist BJ (2017) Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones. J Endocrinol 234(1):R1\u2013R21. https:\/\/doi.org\/10.1530\/JOE-16-0513","journal-title":"J Endocrinol"},{"issue":"4","key":"10507_CR47","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","volume":"75","author":"P Golabi","year":"2021","unstructured":"Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM (2021) Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009\u20132019. J Hepatol 75(4):795\u2013809","journal-title":"J Hepatol"},{"issue":"3","key":"10507_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI162533","volume":"134","author":"S Greatorex","year":"2024","unstructured":"Greatorex S, Kaur S, Xirouchaki CE, Goh PK, Wiede F, Genders AJ, Tran M, Jia YY, Raajendiran A, Brown WA, McLean CA, Sadoshima J, Watt MJ, Tiganis T (2024) Mitochondria- and NOX4-dependent antioxidant defense mitigates progression to nonalcoholic steatohepatitis in obesity. J Clin Investig 134(3):1. https:\/\/doi.org\/10.1172\/JCI162533","journal-title":"J Clin Investig"},{"issue":"Suppl","key":"10507_CR49","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","volume":"29","author":"SK Han","year":"2022","unstructured":"Han SK, Baik SK, Kim MY (2022) Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol 29(Suppl):S5","journal-title":"Clin Mol Hepatol"},{"key":"10507_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2020.607011","volume":"11","author":"T Hendrikx","year":"2020","unstructured":"Hendrikx T, Binder CJ (2020) Oxidation-specific epitopes in non-alcoholic fatty liver disease. Front Endocrinol 11:607011. https:\/\/doi.org\/10.3389\/FENDO.2020.607011","journal-title":"Front Endocrinol"},{"issue":"4","key":"10507_CR51","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/ANTIOX10040565","volume":"10","author":"SM Hewage","year":"2021","unstructured":"Hewage SM, Prashar S, Karmin O, Siow YL (2021) Lingonberry improves non-alcoholic fatty liver disease by reducing hepatic lipid accumulation, oxidative stress and inflammatory response. Antioxidants 10(4):565. https:\/\/doi.org\/10.3390\/ANTIOX10040565","journal-title":"Antioxidants"},{"issue":"8","key":"10507_CR52","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nm.3882","volume":"21","author":"S Hong","year":"2015","unstructured":"Hong S, Moreno-Navarrete JM, Wei X, Kikukawa Y, Tzameli I, Prasad D, Lee Y, Asara JM, Fernandez-Real JM, Maratos-Flier E, Pissios P (2015) Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med 21(8):887\u2013894. https:\/\/doi.org\/10.1038\/nm.3882","journal-title":"Nat Med"},{"key":"10507_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2024.113937","volume":"147","author":"W Hu","year":"2025","unstructured":"Hu W, Gong W, Yang F, Cheng R, Zhang G, Gan L, Zhu Y, Qin W, Gao Y, Li X, Liu J (2025) Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice. Int Immunopharmacol 147:113937. https:\/\/doi.org\/10.1016\/J.INTIMP.2024.113937","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10507_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-J\u00e4rvinen H, Loomba R (2025) Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers 11(1):1\u201325. https:\/\/doi.org\/10.1038\/s41572-025-00599-1","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10507_CR55","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3350\/CMH.2023.0384","volume":"30","author":"J Hwang","year":"2024","unstructured":"Hwang J, Hwang H, Shin H, Kim BH, Kang SH, Yoo JJ, Choi MY, Lee DE, Jun DW, Cho Y (2024) Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: a systematic review and meta-analysis. Clin Mol Hepatol 30(3):561. https:\/\/doi.org\/10.3350\/CMH.2023.0384","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10507_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms9994","volume":"7","author":"T Hy\u00f6tyl\u00e4inen","year":"2016","unstructured":"Hy\u00f6tyl\u00e4inen T, Jerby L, Pet\u00e4j\u00e4 EM, Mattila I, J\u00e4ntti S, Auvinen P, Gastaldelli A, Yki-J\u00e4rvinen H, Ruppin E, Ore\u0161i\u010d M (2016) Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. Nat Commun 7(1):1\u20139. https:\/\/doi.org\/10.1038\/ncomms9994","journal-title":"Nat Commun"},{"issue":"8","key":"10507_CR57","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/40.8.1619276","volume":"40","author":"M Ichikawa","year":"1992","unstructured":"Ichikawa M, Nishino T, Nishino T, Ichikawa A (1992) Subcellular localization of xanthine oxidase in rat hepatocytes: high-resolution immunoelectron microscopic study combined with biochemical analysis. Off J Histochem Soc 40(8):1097\u20131103. https:\/\/doi.org\/10.1177\/40.8.1619276","journal-title":"Off J Histochem Soc"},{"issue":"18","key":"10507_CR58","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/S00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P (2018) Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci 75(18):3313. https:\/\/doi.org\/10.1007\/S00018-018-2860-6","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10507_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/JCM9051369","volume":"9","author":"P Iruzubieta","year":"2020","unstructured":"Iruzubieta P, Medina JM, Fern\u00e1ndez-L\u00f3pez R, Crespo J, de la Cruz F (2020) A role for gut microbiome fermentative pathways in fatty liver disease progression. J Clin Med 9(5):1369. https:\/\/doi.org\/10.3390\/JCM9051369","journal-title":"J Clin Med"},{"issue":"1","key":"10507_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms7555","volume":"6","author":"A Ives","year":"2015","unstructured":"Ives A, Nomura J, Martinon F, Roger T, LeRoy D, Miner JN, Simon G, Busso N, So A (2015) Xanthine oxidoreductase regulates macrophage IL1\u03b2 secretion upon NLRP3 inflammasome activation. Nat Commun 6(1):1\u201311. https:\/\/doi.org\/10.1038\/ncomms7555","journal-title":"Nat Commun"},{"issue":"4","key":"10507_CR61","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/HEP.31118","volume":"72","author":"JX Jiang","year":"2020","unstructured":"Jiang JX, Fish SR, Tomilov A, Li Y, Fan W, Dehnad A, Gae D, Das S, Mozes G, Charville GW, Ramsey J, Cortopassi G, T\u00f6r\u00f6k NJ (2020) Non-phagocytic activation of NOX2 is implicated in progressive non-alcoholic steatohepatitis during aging. Hepatology 72(4):1204. https:\/\/doi.org\/10.1002\/HEP.31118","journal-title":"Hepatology"},{"issue":"2","key":"10507_CR62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.32725\/JAB.2023.009","volume":"21","author":"M Kakimoto","year":"2023","unstructured":"Kakimoto M, Fujii M, Sato I, Honma K, Nakayama H, Kirihara S, Fukuoka T, Ran S, Hirohata S, Kitamori K, Yamamoto S, Watanabe S (2023) Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5\/Dmcr rats. J Appl Biomed 21(2):80\u201390. https:\/\/doi.org\/10.32725\/JAB.2023.009","journal-title":"J Appl Biomed"},{"issue":"3","key":"10507_CR63","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0021-9258(19)45673-1","volume":"247","author":"M Kanda","year":"1972","unstructured":"Kanda M, Brady FO, Rajagopalan KV, Handler P (1972) Studies on the dissociation of flavin adenine dinucleotide from metalloflavoproteins. J Biol Chem 247(3):765\u2013770. https:\/\/doi.org\/10.1016\/S0021-9258(19)45673-1","journal-title":"J Biol Chem"},{"issue":"17","key":"10507_CR64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.144762","volume":"6","author":"Y Kawachi","year":"2021","unstructured":"Kawachi Y, Fujishima Y, Nishizawa H, Nakamura T, Akari S, Murase T, Saito T, Miyazaki Y, Nagao H, Fukuda S, Kita S, Katakami N, Doki Y, Maeda N, Shimomura I (2021) Increased plasma XOR activity induced by NAFLD\/NASH and its possible involvement in vascular neointimal proliferation. JCI Insight 6(17):e144762. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.144762","journal-title":"JCI Insight"},{"issue":"2","key":"10507_CR65","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/J.CBI.2007.05.008","volume":"169","author":"SH Ki","year":"2007","unstructured":"Ki SH, Choi JH, Kim CW, Kim SG (2007) Combined metadoxine and garlic oil treatment efficaciously abrogates alcoholic steatosis and CYP2E1 induction in rat liver with restoration of AMPK activity. Chem Biol Interact 169(2):80\u201390. https:\/\/doi.org\/10.1016\/J.CBI.2007.05.008","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10507_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-02325-2","volume":"8","author":"SY Kim","year":"2017","unstructured":"Kim SY, Jeong JM, Kim SJ, Seo W, Kim MH, Choi WM, Yoo W, Lee JH, Shim YR, Yi HS, Lee YS, Eun HS, Lee BS, Chun K, Kang SJ, Kim SC, Gao B, Kunos G, Kim HM, Jeong WI (2017) Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4\u2013MD2 complex. Nat Commun 8(1):1\u201315. https:\/\/doi.org\/10.1038\/s41467-017-02325-2","journal-title":"Nat Commun"},{"issue":"2","key":"10507_CR67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2133\/DMPK.21.83","volume":"21","author":"S Kitamura","year":"2006","unstructured":"Kitamura S, Sugihara K, Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21(2):83\u201398. https:\/\/doi.org\/10.2133\/DMPK.21.83","journal-title":"Drug Metab Pharmacokinet"},{"issue":"10","key":"10507_CR68","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/HEP4.1566","volume":"4","author":"AC Koop","year":"2020","unstructured":"Koop AC, Thiele ND, Steins D, Micha\u00eblsson E, Wehmeyer M, Scheja L, Steglich B, Huber S, Schulze zur Wiesch J, Lohse AW, Heeren J, Kluwe J (2020) Therapeutic targeting of myeloperoxidase attenuates NASH in mice. Hepatol Commun 4(10):1441. https:\/\/doi.org\/10.1002\/HEP4.1566","journal-title":"Hepatol Commun"},{"issue":"1","key":"10507_CR69","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/S-2001-12932\/ID\/25\/BIB","volume":"21","author":"A Koteish","year":"2001","unstructured":"Koteish A, Diehl AM (2001) Animal models of steatosis. Semin Liver Dis 21(1):89\u2013104. https:\/\/doi.org\/10.1055\/S-2001-12932\/ID\/25\/BIB","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10507_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES11030754","volume":"11","author":"Y Kotozaki","year":"2023","unstructured":"Kotozaki Y, Satoh M, Nasu T, Tanno K, Tanaka F, Sasaki M (2023) Human plasma xanthine oxidoreductase activity in cardiovascular disease: evidence from a population-based study. Biomedicines 11(3):754. https:\/\/doi.org\/10.3390\/BIOMEDICINES11030754","journal-title":"Biomedicines"},{"key":"10507_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/J.DYEPIG.2022.110132","volume":"200","author":"N Kwon","year":"2022","unstructured":"Kwon N, Chen Y, Chen X, Kim MH, Yoon J (2022) Recent progress on small molecule-based fluorescent imaging probes for hypochlorous acid (HOCl)\/hypochlorite (OCl\u2212). Dyes Pigments 200:110132. https:\/\/doi.org\/10.1016\/J.DYEPIG.2022.110132","journal-title":"Dyes Pigments"},{"key":"10507_CR72","doi-asserted-by":"publisher","DOI":"10.1152\/AJPGI.00153.2023\/ASSET\/IMAGES\/MEDIUM\/GI-00153-2023R01.PNG","author":"S Larion","year":"2024","unstructured":"Larion S, Padgett CA, Mintz JD, Thompson JA, Butcher JT, Belin de Chantemele EJ, Haigh S, Khurana S, Fulton DJ, Stepp DW (2024) NADPH oxidase 1 promotes hepatic steatosis in obese mice and is abrogated by augmented skeletal muscle mass. Am J Physiol Gastrointest Liver Physiol. https:\/\/doi.org\/10.1152\/AJPGI.00153.2023\/ASSET\/IMAGES\/MEDIUM\/GI-00153-2023R01.PNG","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"12","key":"10507_CR73","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J (2022) 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 20(12):2809\u20132817","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10507_CR74","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/J.JHEP.2018.06.008","volume":"69","author":"C Lebeaupin","year":"2018","unstructured":"Lebeaupin C, Vall\u00e9e D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B (2018) Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol 69(4):927\u2013947. https:\/\/doi.org\/10.1016\/J.JHEP.2018.06.008","journal-title":"J Hepatol"},{"issue":"3","key":"10507_CR75","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/J.TOXLET.2006.07.305","volume":"166","author":"JY Lee","year":"2006","unstructured":"Lee JY, Jung GY, Heo HJ, Yun MR, Park JY, Bae SS, Hong KW, Lee WS, Kim CD (2006) 4-hydroxynonenal induces vascular smooth muscle cell apoptosis through mitochondrial generation of reactive oxygen species. Toxicol Lett 166(3):212\u2013221. https:\/\/doi.org\/10.1016\/J.TOXLET.2006.07.305","journal-title":"Toxicol Lett"},{"issue":"2","key":"10507_CR76","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1515\/CCLM.2010.037","volume":"48","author":"YJ Lee","year":"2010","unstructured":"Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY (2010) Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med 48(2):175\u2013180. https:\/\/doi.org\/10.1515\/CCLM.2010.037","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"10507_CR77","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/BIOMEDICINES10061216\/S1","volume":"10","author":"KS Lee","year":"2022","unstructured":"Lee KS, Cho Y, Kim H, Hwang H, Cho JW, Lee YH, Lee SG (2022) Association of metabolomic change and treatment response in patients with non-alcoholic fatty liver disease. Biomedicines 10(6):1216. https:\/\/doi.org\/10.3390\/BIOMEDICINES10061216\/S1","journal-title":"Biomedicines"},{"issue":"5","key":"10507_CR78","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/J.JHEP.2008.11.021","volume":"50","author":"Y Li","year":"2009","unstructured":"Li Y, Xu C, Yu C, Xu L, Miao M (2009) Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 50(5):1029\u20131034. https:\/\/doi.org\/10.1016\/J.JHEP.2008.11.021","journal-title":"J Hepatol"},{"key":"10507_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/MNFR.202300480","author":"L Li","year":"2023","unstructured":"Li L, Ji K, Du F, Jin N, Boesch C, Farag MA, Li H, Liu X, Xiao J (2023) Does flavonoid supplementation alleviate non-alcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials. Mol Nutr Food Res. https:\/\/doi.org\/10.1002\/MNFR.202300480","journal-title":"Mol Nutr Food Res"},{"key":"10507_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2021.108306","volume":"104","author":"L Liang","year":"2022","unstructured":"Liang L, Ye S, Jiang R, Zhou X, Zhou J, Meng S (2022) Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1\/AMPK signaling. Int Immunopharmacol 104:108306. https:\/\/doi.org\/10.1016\/J.INTIMP.2021.108306","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"10507_CR81","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1124\/DMD.107.015107","volume":"35","author":"AJ Lickteig","year":"2007","unstructured":"Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, Cherrington NJ (2007) Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 35(10):1970\u20131978. https:\/\/doi.org\/10.1124\/DMD.107.015107","journal-title":"Drug Metab Dispos"},{"key":"10507_CR82","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1470380","author":"N Liu","year":"2021","unstructured":"Liu N, Xu H, Sun Q, Yu X, Chen W, Wei H, Jiang J, Xu Y, Lu W (2021) The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors. Oxid Med Cell Longev. https:\/\/doi.org\/10.1155\/2021\/1470380","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"10507_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-34654-2","volume":"13","author":"Z Lu","year":"2023","unstructured":"Lu Z, Liu L, Zhao S, Zhao J, Li S, Li M (2023) Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice. Sci Rep 13(1):1\u201311. https:\/\/doi.org\/10.1038\/s41598-023-34654-2","journal-title":"Sci Rep"},{"issue":"1","key":"10507_CR84","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/J.JPBA.2009.12.016","volume":"52","author":"Y Lv","year":"2010","unstructured":"Lv Y, Liu X, Yan S, Liang X, Yang Y, Dai W, Zhang W (2010) Metabolomic study of myocardial ischemia and intervention effects of compound Danshen tablets in rats using ultra-performance liquid chromatography\/quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal 52(1):129\u2013135. https:\/\/doi.org\/10.1016\/J.JPBA.2009.12.016","journal-title":"J Pharm Biomed Anal"},{"key":"10507_CR85","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/J.JNUTBIO.2019.05.015","volume":"71","author":"Y Lv","year":"2019","unstructured":"Lv Y, Gao X, Luo Y, Fan W, Shen T, Ding C, Yao M, Song S, Yan L (2019) Apigenin ameliorates HFD-induced NAFLD through regulation of the XO\/NLRP3 pathways. J Nutr Biochem 71:110\u2013121. https:\/\/doi.org\/10.1016\/J.JNUTBIO.2019.05.015","journal-title":"J Nutr Biochem"},{"issue":"1","key":"10507_CR86","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/ANTIOX11010091","volume":"11","author":"Y Ma","year":"2021","unstructured":"Ma Y, Lee G, Heo SY, Roh YS (2021) Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease. Antioxidants 11(1):91. https:\/\/doi.org\/10.3390\/ANTIOX11010091","journal-title":"Antioxidants"},{"key":"10507_CR87","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/J.REDOX.2015.08.006","volume":"6","author":"R Mashima","year":"2015","unstructured":"Mashima R, Okuyama T (2015) The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol 6:297\u2013310. https:\/\/doi.org\/10.1016\/J.REDOX.2015.08.006","journal-title":"Redox Biol"},{"issue":"5","key":"10507_CR88","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1042\/BST0391240","volume":"39","author":"KA Massey","year":"2011","unstructured":"Massey KA, Nicolaou A (2011) Lipidomics of polyunsaturated-fatty-acid-derived oxygenated metabolites. Biochem Soc Trans 39(5):1240\u20131246. https:\/\/doi.org\/10.1042\/BST0391240","journal-title":"Biochem Soc Trans"},{"key":"10507_CR89","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/J.FREERADBIOMED.2017.12.019","volume":"115","author":"M Matsumoto","year":"2018","unstructured":"Matsumoto M, Zhang J, Zhang X, Liu J, Jiang JX, Yamaguchi K, Taruno A, Katsuyama M, Iwata K, Ibi M, Cui W, Matsuno K, Marunaka Y, Itoh Y, Torok NJ, Yabe-Nishimura C (2018) The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease. Free Radic Biol Med 115:412\u2013420. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2017.12.019","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10507_CR90","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3109\/03602532.2011.577781","volume":"43","author":"MD Merrell","year":"2011","unstructured":"Merrell MD, Cherrington NJ (2011) Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev 43(3):317. https:\/\/doi.org\/10.3109\/03602532.2011.577781","journal-title":"Drug Metab Rev"},{"key":"10507_CR91","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/J.CCR.2018.04.006","volume":"368","author":"C Mota","year":"2018","unstructured":"Mota C, Coelho C, Leimk\u00fchler S, Garattini E, Terao M, Santos-Silva T, Rom\u00e3o MJ (2018) Critical overview on the structure and metabolism of human aldehyde oxidase and its role in pharmacokinetics. Coord Chem Rev 368:35\u201359. https:\/\/doi.org\/10.1016\/J.CCR.2018.04.006","journal-title":"Coord Chem Rev"},{"key":"10507_CR92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cotox.2019.03.001","volume":"16","author":"FA M\u00fcller","year":"2019","unstructured":"M\u00fcller FA, Sturla SJ (2019) Human in vitro models of nonalcoholic fatty liver disease. Curr Opin Toxicol 16:9\u201316. https:\/\/doi.org\/10.1016\/j.cotox.2019.03.001","journal-title":"Curr Opin Toxicol"},{"issue":"1","key":"10507_CR93","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1152\/AJPGI.00443.2014","volume":"309","author":"Y Nakatsu","year":"2015","unstructured":"Nakatsu Y, Seno Y, Kushiyama A, Sakoda H, Fujishiro M, Katasako A, Mori K, Matsunaga Y, Fukushima T, Kanaoka R, Yamamotoya T, Kamata H, Asano T (2015) The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointest Liver Physiol 309(1):42\u201351. https:\/\/doi.org\/10.1152\/AJPGI.00443.2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"10507_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/ANTIOX11061131","volume":"11","author":"A Nasc\u00e8","year":"2022","unstructured":"Nasc\u00e8 A, Gariani K, Jornayvaz FR, Szanto I (2022) NADPH oxidases connecting fatty liver disease, insulin resistance and type 2 diabetes: current knowledge and therapeutic outlook. Antioxidants 11(6):1131. https:\/\/doi.org\/10.3390\/ANTIOX11061131","journal-title":"Antioxidants"},{"issue":"3","key":"10507_CR95","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/J.BBRC.2006.09.101","volume":"350","author":"M Neumeier","year":"2006","unstructured":"Neumeier M, Weigert J, Sch\u00e4ffler A, Weiss TS, Schmidl C, B\u00fcttner R, Bollheimer C, Aslanidis C, Sch\u00f6lmerich J, Buechler C (2006) Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun 350(3):731\u2013735. https:\/\/doi.org\/10.1016\/J.BBRC.2006.09.101","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"10507_CR96","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMOA2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling A-S, Harrison SA (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384(12):1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMOA2028395","journal-title":"N Engl J Med"},{"issue":"4","key":"10507_CR97","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3350\/cmh.2022.0239","volume":"28","author":"MH Nguyen","year":"2022","unstructured":"Nguyen MH, Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R (2022) Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol 28(4):841\u2013850. https:\/\/doi.org\/10.3350\/cmh.2022.0239","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10507_CR98","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/J.LIVRES.2018.03.003","volume":"2","author":"L Niederreiter","year":"2018","unstructured":"Niederreiter L, Tilg H (2018) Cytokines and fatty liver diseases. Liver Res 2(1):14\u201320. https:\/\/doi.org\/10.1016\/J.LIVRES.2018.03.003","journal-title":"Liver Res"},{"issue":"1","key":"10507_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-57784-3","volume":"10","author":"T Nishikawa","year":"2020","unstructured":"Nishikawa T, Nagata N, Shimakami T, Shirakura T, Matsui C, Ni Y, Zhuge F, Xu L, Chen G, Nagashimada M, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S, Ota T (2020) Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep 10(1):1\u201311. https:\/\/doi.org\/10.1038\/s41598-020-57784-3","journal-title":"Sci Rep"},{"issue":"1","key":"10507_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-53965-x","volume":"9","author":"J Nomura","year":"2019","unstructured":"Nomura J, Kobayashi T, So A, Busso N (2019) Febuxostat, a xanthine oxidoreductase inhibitor, decreases NLRP3-dependent inflammation in macrophages by activating the purine salvage pathway and restoring cellular bioenergetics. Sci Rep 9(1):1\u201310. https:\/\/doi.org\/10.1038\/s41598-019-53965-x","journal-title":"Sci Rep"},{"issue":"2","key":"10507_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/MEDICINA55020026","volume":"55","author":"A Ore","year":"2019","unstructured":"Ore A, Akinloye OA (2019) Oxidative stress and antioxidant biomarkers in clinical and experimental models of non-alcoholic fatty liver disease. Medicina (b Aires) 55(2):26. https:\/\/doi.org\/10.3390\/MEDICINA55020026","journal-title":"Medicina (b Aires)"},{"issue":"5","key":"10507_CR102","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/hep.32228","volume":"75","author":"JM Paik","year":"2022","unstructured":"Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, Younossi ZM (2022) Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology 75(5):1204\u20131217. https:\/\/doi.org\/10.1002\/hep.32228","journal-title":"Hepatology"},{"key":"10507_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/J.REDOX.2021.101947","volume":"41","author":"MW Park","year":"2021","unstructured":"Park MW, Cha HW, Kim J, Kim JH, Yang H, Yoon S, Boonpraman N, Yi SS, Yoo ID, Moon JS (2021) NOX4 promotes ferroptosis of astrocytes by oxidative stress-induced lipid peroxidation via the impairment of mitochondrial metabolism in Alzheimer\u2019s diseases. Redox Biol 41:101947. https:\/\/doi.org\/10.1016\/J.REDOX.2021.101947","journal-title":"Redox Biol"},{"issue":"1","key":"10507_CR104","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/TP.0000000000002480","volume":"103","author":"I Pierantonelli","year":"2019","unstructured":"Pierantonelli I, Svegliati-Baroni G (2019) Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation 103(1):E1\u2013E13. https:\/\/doi.org\/10.1097\/TP.0000000000002480","journal-title":"Transplantation"},{"issue":"10290","key":"10507_CR105","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M (2021) Non-alcoholic fatty liver disease. Lancet 397(10290):2212\u20132224","journal-title":"Lancet"},{"issue":"24","key":"10507_CR106","doi-asserted-by":"publisher","first-page":"8441","DOI":"10.1021\/JM100888D","volume":"53","author":"DC Pryde","year":"2010","unstructured":"Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, Tran TD (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53(24):8441\u20138460. https:\/\/doi.org\/10.1021\/JM100888D","journal-title":"J Med Chem"},{"key":"10507_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.628583","volume":"12","author":"S Pu","year":"2021","unstructured":"Pu S, Li Y, Liu Q, Zhang X, Chen L, Li R, Zhang J, Wu T, Tang Q, Yang X, Zhang Z, Huang Y, Kuang J, Li H, Zou M, Jiang W, He J (2021) Inhibition of 5-lipoxygenase in hepatic stellate cells alleviates liver fibrosis. Front Pharmacol 12:628583. https:\/\/doi.org\/10.3389\/fphar.2021.628583","journal-title":"Front Pharmacol"},{"issue":"1","key":"10507_CR108","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J et al (2023) Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 8(1):20\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(22)00317","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10507_CR109","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2353\/AJPATH.2009.080999","volume":"175","author":"SS Rensen","year":"2009","unstructured":"Rensen SS, Slaats Y, Nijhuis J, Jans A, Bieghs V, Driessen A, Malle E, Greve JW, Buurman WA (2009) Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol 175(4):1473\u20131482. https:\/\/doi.org\/10.2353\/AJPATH.2009.080999","journal-title":"Am J Pathol"},{"issue":"9","key":"10507_CR110","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7(9):851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10507_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2023.100485","volume":"65","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Sookoian S (2024) From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res 65(1):100485. https:\/\/doi.org\/10.1016\/j.jlr.2023.100485","journal-title":"J Lipid Res"},{"issue":"2","key":"10507_CR112","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/S004410100361","volume":"304","author":"MJ Rodr\u00edguez","year":"2001","unstructured":"Rodr\u00edguez MJ, Saura J, Billett EE, Finch CC, Mahy N (2001) Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system. Cell Tissue Res 304(2):215\u2013220. https:\/\/doi.org\/10.1007\/S004410100361","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10507_CR113","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI77812","volume":"126","author":"VT Samuel","year":"2016","unstructured":"Samuel VT, Shulman GI (2016) The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 126(1):12\u201322. https:\/\/doi.org\/10.1172\/JCI77812","journal-title":"J Clin Invest"},{"key":"10507_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2024.1433857","volume":"12","author":"R Sandireddy","year":"2024","unstructured":"Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK (2024) Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol 12:1433857. https:\/\/doi.org\/10.3389\/FCELL.2024.1433857","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10507_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-45009-1","volume":"9","author":"S Sarkar","year":"2019","unstructured":"Sarkar S, Kimono D, Albadrani M, Seth RK, Busbee P, Alghetaa H, Porter DE, Scott GI, Brooks B, Nagarkatti M, Nagarkatti P, Chatterjee S (2019) Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of nonalcoholic fatty liver disease. Sci Rep 9(1):1\u201322. https:\/\/doi.org\/10.1038\/s41598-019-45009-1","journal-title":"Sci Rep"},{"issue":"4","key":"10507_CR116","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/MOL.0B013E32833B7782","volume":"21","author":"DB Savage","year":"2010","unstructured":"Savage DB, Semple RK (2010) Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 21(4):329\u2013336. https:\/\/doi.org\/10.1097\/MOL.0B013E32833B7782","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"10507_CR117","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/J.BBALIP.2013.08.016","volume":"1841","author":"J Schleicher","year":"2014","unstructured":"Schleicher J, Guthke R, Dahmen U, Dirsch O, Holzhuetter HG, Schuster S (2014) A theoretical study of lipid accumulation in the liver\u2014implications for nonalcoholic fatty liver disease. Biochimica Et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1841(1):62\u201369. https:\/\/doi.org\/10.1016\/J.BBALIP.2013.08.016","journal-title":"Biochimica Et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"},{"issue":"7","key":"10507_CR118","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0021-9681(70)90056-1","volume":"23","author":"HA Schroeder","year":"1970","unstructured":"Schroeder HA, Balassa JJ, Tipton IH (1970) Essential trace metals in man: molybdenum. J Chronic Dis 23(7):481\u2013499. https:\/\/doi.org\/10.1016\/0021-9681(70)90056-1","journal-title":"J Chronic Dis"},{"issue":"3","key":"10507_CR119","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1042\/BJ2680579","volume":"268","author":"S Shaw","year":"1990","unstructured":"Shaw S, Jayatilleke E (1990) The role of aldehyde oxidase in ethanol-induced hepatic lipid peroxidation in the rat. Biochem J 268(3):579\u2013583. https:\/\/doi.org\/10.1042\/BJ2680579","journal-title":"Biochem J"},{"issue":"1","key":"10507_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/JEBM.70002","volume":"18","author":"R Shi","year":"2025","unstructured":"Shi R, Chai K, Wang H, Zhou J, Yang S, Li J, Qiao C, Sheng X, Zhang X, Wu J (2025) Clinical assessment of common medications for nonalcoholic fatty liver disease: a systematic review and Bayesian network meta-analysis. J Evid Based Med 18(1):e70002. https:\/\/doi.org\/10.1111\/JEBM.70002","journal-title":"J Evid Based Med"},{"issue":"1","key":"10507_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-69675-8","volume":"10","author":"JC Simard","year":"2020","unstructured":"Simard JC et al (2020) Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease. Sci Rep 10(1):1\u201316. https:\/\/doi.org\/10.1038\/s41598-020-69675-8","journal-title":"Sci Rep"},{"issue":"1","key":"10507_CR122","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/LIVERS2010003","volume":"2","author":"C Smirne","year":"2022","unstructured":"Smirne C, Croce E, Di Benedetto D, Cantaluppi V, Comi C, Sainaghi PP, Minisini R, Grossini E, Pirisi M (2022) Oxidative stress in non-alcoholic fatty liver disease. Livers 2(1):30\u201376. https:\/\/doi.org\/10.3390\/LIVERS2010003","journal-title":"Livers"},{"issue":"1","key":"10507_CR123","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/S12033-007-0057-6","volume":"37","author":"G Spiteller","year":"2007","unstructured":"Spiteller G (2007) The important role of lipid peroxidation processes in aging and age dependent diseases. Mol Biotechnol 37(1):5\u201312. https:\/\/doi.org\/10.1007\/S12033-007-0057-6","journal-title":"Mol Biotechnol"},{"key":"10507_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.CELLIMM.2017.05.002","volume":"317","author":"A Strzepa","year":"2017","unstructured":"Strzepa A, Pritchard KA, Dittel BN (2017) Myeloperoxidase: a new player in autoimmunity. Cell Immunol 317:1\u20138. https:\/\/doi.org\/10.1016\/J.CELLIMM.2017.05.002","journal-title":"Cell Immunol"},{"key":"10507_CR125","unstructured":"Study Details | A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)\/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)\/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06161571"},{"key":"10507_CR126","unstructured":"Study Details | Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05574036"},{"key":"10507_CR127","unstructured":"Study Details | Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04772352"},{"key":"10507_CR128","unstructured":"Study Details | Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05474560"},{"key":"10507_CR129","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8954201","author":"A Sturza","year":"2019","unstructured":"Sturza A, Popoiu CM, Ionica M, Duicu OM, Olariu S, Muntean DM, Boia ES (2019) Monoamine oxidase-related vascular oxidative stress in diseases associated with inflammatory burden. Oxidative Med Cell Longev. https:\/\/doi.org\/10.1155\/2019\/8954201","journal-title":"Oxidative Med Cell Longev"},{"issue":"6","key":"10507_CR130","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1021\/ACS.MOLPHARMACEUT.3C01147\/SUPPL_FILE\/MP3C01147_SI_001.PDF","volume":"21","author":"S Subash","year":"2024","unstructured":"Subash S, Singh DK, Ahire D, Khojasteh SC, Murray BP, Zientek MA, Jones RS, Kulkarni P, Zubair F, Smith BJ, Heyward S, Leeder JS, Prasad B (2024) Ontogeny of Human Liver Aldehyde Oxidase: Developmental Changes and Implications for Drug Metabolism. Mol Pharm 21(6):2740\u20132750. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.3C01147\/SUPPL_FILE\/MP3C01147_SI_001.PDF","journal-title":"Mol Pharm"},{"issue":"8","key":"10507_CR131","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/10715762.2019.1635691","volume":"53","author":"M \u015awiderska","year":"2019","unstructured":"\u015awiderska M, Maciejczyk M, Zalewska A, Pogorzelska J, Flisiak R, Chabowski A (2019) Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients. Free Radic Res 53(8):841\u2013850. https:\/\/doi.org\/10.1080\/10715762.2019.1635691","journal-title":"Free Radic Res"},{"issue":"1\u20134","key":"10507_CR132","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bbrc.2018.11.008","volume":"507","author":"K Takeuchi","year":"2018","unstructured":"Takeuchi K, Yokouchi C, Goto H, Umehara K, Yamada H, Ishii Y (2018) Alleviation of fatty liver in a rat model by enhancing N 1 -methylnicotinamide bioavailability through aldehyde oxidase inhibition. Biochem Biophys Res Commun 507(1\u20134):203\u2013210. https:\/\/doi.org\/10.1016\/j.bbrc.2018.11.008","journal-title":"Biochem Biophys Res Commun"},{"key":"10507_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2022.1005312","volume":"13","author":"P Tan","year":"2022","unstructured":"Tan P, Jin L, Qin X, He B (2022) Natural flavonoids: potential therapeutic strategies for non-alcoholic fatty liver disease. Front Pharmacol 13:1005312. https:\/\/doi.org\/10.3389\/FPHAR.2022.1005312","journal-title":"Front Pharmacol"},{"issue":"3","key":"10507_CR134","first-page":"545","volume":"32","author":"W Tang","year":"2018","unstructured":"Tang W, Mu J, Chen QI, Li X, Liu H (2018) The involvement and mechanism of febuxostat in non-alcoholic fatty liver disease cells. J Biol Regul Homeost Agents 32(3):545\u2013551","journal-title":"J Biol Regul Homeost Agents"},{"key":"10507_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.870239","volume":"13","author":"SP Tang","year":"2022","unstructured":"Tang SP, Mao XL, Chen YH, Yan LL, Ye LP, Li SW (2022) Reactive oxygen species induce fatty liver and ischemia-reperfusion injury by promoting inflammation and cell death. Front Immunol 13:870239. https:\/\/doi.org\/10.3389\/FIMMU.2022.870239","journal-title":"Front Immunol"},{"issue":"4","key":"10507_CR136","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/S00204-016-1683-1","volume":"90","author":"M Terao","year":"2016","unstructured":"Terao M, Rom\u00e3o MJ, Leimk\u00fchler S, Bolis M, Fratelli M, Coelho C, Santos-Silva T, Garattini E (2016) Structure and function of mammalian aldehyde oxidases. Arch Toxicol 90(4):753\u2013780. https:\/\/doi.org\/10.1007\/S00204-016-1683-1","journal-title":"Arch Toxicol"},{"issue":"16","key":"10507_CR137","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1074\/JBC.REV119.007741","volume":"295","author":"M Terao","year":"2020","unstructured":"Terao M, Garattini E, Rom\u00e3o MJ, Leimk\u00fchler S (2020) Evolution, expression, and substrate specificities of aldehyde oxidase enzymes in eukaryotes. J Biol Chem 295(16):5377\u20135389. https:\/\/doi.org\/10.1074\/JBC.REV119.007741","journal-title":"J Biol Chem"},{"key":"10507_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2023.109901","author":"Z Tian","year":"2023","unstructured":"Tian Z, Wang X, Han T, Sun C (2023) Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice. Int Immunopharmacol. https:\/\/doi.org\/10.1016\/J.INTIMP.2023.109901","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10507_CR139","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/J.ARCMED.2021.04.005","volume":"52","author":"P Toledo-Ibelles","year":"2021","unstructured":"Toledo-Ibelles P, Guti\u00e9rrez-Vidal R, Calixto-Tlacomulco S, Delgado-Coello B, Mas-Oliva J (2021) Hepatic accumulation of hypoxanthine: a link between hyperuricemia and nonalcoholic fatty liver disease. Arch Med Res 52(7):692\u2013702. https:\/\/doi.org\/10.1016\/J.ARCMED.2021.04.005","journal-title":"Arch Med Res"},{"issue":"8","key":"10507_CR140","doi-asserted-by":"publisher","DOI":"10.15252\/EMMM.201809903","volume":"11","author":"MC Ty","year":"2019","unstructured":"Ty MC, Zuniga M, G\u00f6tz A, Kayal S, Sahu PK, Mohanty A, Mohanty S, Wassmer SC, Rodriguez A (2019) Malaria inflammation by xanthine oxidase-produced reactive oxygen species. EMBO Mol Med 11(8):9903. https:\/\/doi.org\/10.15252\/EMMM.201809903","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10507_CR141","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/S00018-012-1065-7","volume":"70","author":"CC Wang","year":"2012","unstructured":"Wang CC, Billett E, Borchert A, Kuhn H, Ufer C (2012) Monoamine oxidases in development. Cell Mol Life Sci 70(4):599\u2013630. https:\/\/doi.org\/10.1007\/S00018-012-1065-7","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10507_CR142","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3892\/MMR.2016.6025","volume":"15","author":"B Wang","year":"2017","unstructured":"Wang B, Yang RN, Zhu YR, Xing JC, Lou XW, He YJ, Ding QL, Zhang MY, Qiu H (2017) Involvement of xanthine oxidase and paraoxonase 1 in the process of oxidative stress in nonalcoholic fatty liver disease. Mol Med Rep 15(1):387\u2013395. https:\/\/doi.org\/10.3892\/MMR.2016.6025","journal-title":"Mol Med Rep"},{"issue":"1","key":"10507_CR143","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1042\/CS20220477","volume":"137","author":"SH Wang","year":"2023","unstructured":"Wang SH, Tsai FC, Lin HH, Yu TY, Kuo CH, Li HY, Lin MS (2023) Inhibition of monoamine oxidase B reduces atherosclerosis and fatty liver in mice. Clin Sci 137(1):17\u201330. https:\/\/doi.org\/10.1042\/CS20220477","journal-title":"Clin Sci"},{"key":"10507_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2024.116405","volume":"173","author":"S Wang","year":"2024","unstructured":"Wang S, Li X, Zhang B, Li Y, Chen K, Qi H, Gao M, Rong J, Liu L, Wan Y, Dong X, Yan M, Ma L, Li P, Zhao T (2024) Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: a 16S rRNA and non-targeted metabolomics analyses. Biomed Pharmacother 173:116405. https:\/\/doi.org\/10.1016\/J.BIOPHA.2024.116405","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10507_CR145","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/J.JHEP.2015.01.019","volume":"62","author":"C Xu","year":"2015","unstructured":"Xu C, Wan X, Xu L, Weng H, Yan M, Miao M, Sun Y, Xu G, Dooley S, Li Y, Yu C (2015) Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds. J Hepatol 62(6):1412\u20131419. https:\/\/doi.org\/10.1016\/J.JHEP.2015.01.019","journal-title":"J Hepatol"},{"issue":"1","key":"10507_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12986-025-00927-Y\/FIGURES\/5","volume":"22","author":"M Xu","year":"2025","unstructured":"Xu M, Gong R, Xie J, Xu S, Wang S (2025) Clinical characteristics of lean and non-lean non-alcoholic fatty liver disease: a cross-sectional study. Nutr Metab 22(1):1\u201312. https:\/\/doi.org\/10.1186\/S12986-025-00927-Y\/FIGURES\/5","journal-title":"Nutr Metab"},{"key":"10507_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2022.106426","volume":"184","author":"P Yadav","year":"2022","unstructured":"Yadav P, Khurana A, Bhatti JS, Weiskirchen R, Navik U (2022) Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: an experimental to clinical perspective. Pharmacol Res 184:106426. https:\/\/doi.org\/10.1016\/J.PHRS.2022.106426","journal-title":"Pharmacol Res"},{"issue":"1","key":"10507_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-16688-0","volume":"12","author":"C Yagi","year":"2022","unstructured":"Yagi C, Kusunoki Y, Tsunoda T, Murase T, Nakamura T, Osugi K, Ohigashi M, Morimoto A, Miyoshi A, Kakutani-Hatayama M, Kosaka-Hamamoto K, Kadoya M, Konishi K, Shoji T, Koyama H (2022) Xanthine oxidoreductase activity is correlated with hepatic steatosis. Sci Rep 12(1):1\u20139. https:\/\/doi.org\/10.1038\/s41598-022-16688-0","journal-title":"Sci Rep"},{"issue":"1","key":"10507_CR149","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2131\/JTS.46.31","volume":"46","author":"C Yokouchi","year":"2021","unstructured":"Yokouchi C, Nishimura Y, Goto H, Sato M, Hidoh Y, Takeuchi K, Ishii Y (2021) Reduction of fatty liver in rats by nicotinamide via the regeneration of the methionine cycle and the inhibition of aldehyde oxidase. J Toxicol Sci 46(1):31\u201342. https:\/\/doi.org\/10.2131\/JTS.46.31","journal-title":"J Toxicol Sci"},{"issue":"3","key":"10507_CR150","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/J.GASTRO.2020.11.051","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Corey KE, Lim JK (2021) AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology 160(3):912\u2013918. https:\/\/doi.org\/10.1053\/J.GASTRO.2020.11.051","journal-title":"Gastroenterology"},{"issue":"4","key":"10507_CR151","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77(4):1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"issue":"12","key":"10507_CR152","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/APT.70196","volume":"61","author":"M Zafer","year":"2025","unstructured":"Zafer M, Tavaglione F, Romero-G\u00f3mez M, Loomba R (2025) Review article: GLP-1 receptor agonists and glucagon\/GIP\/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD. Aliment Pharmacol Ther 61(12):1872\u20131888. https:\/\/doi.org\/10.1111\/APT.70196","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10507_CR153","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3390\/ANTIOX9070578","volume":"9","author":"S Zelber-Sagi","year":"2020","unstructured":"Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss-Isakov N, Hahn M, Webb M, Shibolet O, Kariv R, Tirosh O (2020) Serum malondialdehyde is associated with non-alcoholic fatty liver and related liver damage differentially in men and women. Antioxidants 9(7):578. https:\/\/doi.org\/10.3390\/ANTIOX9070578","journal-title":"Antioxidants"},{"issue":"9","key":"10507_CR154","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1074\/jbc.M116.763532","volume":"292","author":"J Zeng","year":"2017","unstructured":"Zeng J, Deng S, Wang Y, Li P, Tang L, Pang Y (2017) Specific inhibition of acyl-CoA oxidase-1 by an acetylenic acid improves hepatic lipid and Reactive Oxygen Species (ROS) metabolism in rats fed a high fat diet. J Biol Chem 292(9):3800\u20133809. https:\/\/doi.org\/10.1074\/jbc.M116.763532","journal-title":"J Biol Chem"},{"key":"10507_CR155","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1080152","author":"J Zhang","year":"2020","unstructured":"Zhang J, Chen Y, Liu C, Li L, Li P (2020) N1-methylnicotinamide improves hepatic insulin sensitivity via activation of SIRT1 and inhibition of FOXO1 acetylation. J Diabetes Res. https:\/\/doi.org\/10.1155\/2020\/1080152","journal-title":"J Diabetes Res"},{"issue":"1","key":"10507_CR156","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/S13578-024-01267-9","volume":"14","author":"J Zhang","year":"2024","unstructured":"Zhang J, Li Y, Yang L, Ma N, Qian S, Chen Y, Duan Y, Xiang X, He Y (2024a) New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease. Cell Biosci 14(1):90. https:\/\/doi.org\/10.1186\/S13578-024-01267-9","journal-title":"Cell Biosci"},{"key":"10507_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/J.JEP.2024.117828","volume":"325","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhang J, Zhou Z, Xiong P, Cheng L, Ma J, Wen Y, Shen T, He X, Wang L, Zhang Y, Xiao C (2024b) Integrated network pharmacology, metabolomics, and transcriptomics of Huanglian-Hongqu herb pair in non-alcoholic fatty liver disease. J Ethnopharmacol 325:117828. https:\/\/doi.org\/10.1016\/J.JEP.2024.117828","journal-title":"J Ethnopharmacol"},{"key":"10507_CR158","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/J.BIOPHA.2017.10.035","volume":"97","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Ding YL, Zhang JL, Zhang P, Wang JQ, Li ZH (2018) Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism. Biomed Pharmacother 97:1397\u20131408. https:\/\/doi.org\/10.1016\/J.BIOPHA.2017.10.035","journal-title":"Biomed Pharmacother"},{"key":"10507_CR159","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/03602532.2023.2202359","volume":"55","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Chen L, He Y, Qin L, Tan D, Bai Z, Song Y, Wang YH (2023) The alteration of drug metabolism enzymes and pharmacokinetic parameters in nonalcoholic fatty liver disease: current animal models and clinical practice. Drug Metab Rev 55:163\u2013180. https:\/\/doi.org\/10.1080\/03602532.2023.2202359","journal-title":"Drug Metab Rev"}],"container-title":["Journal of Molecular Histology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-025-10507-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10735-025-10507-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-025-10507-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:28:22Z","timestamp":1757269702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10735-025-10507-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":159,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10507"],"URL":"https:\/\/doi.org\/10.1007\/s10735-025-10507-2","relation":{},"ISSN":["1567-2379","1567-2387"],"issn-type":[{"value":"1567-2379","type":"print"},{"value":"1567-2387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}